Long-term follow-up of intravesical bacillus Calmette-Guérin treatment for superficial transitional-cell carcinoma of the bladder involving the prostatic urethra
- PMID: 17956711
- DOI: 10.3816/CGC.2007.n.021
Long-term follow-up of intravesical bacillus Calmette-Guérin treatment for superficial transitional-cell carcinoma of the bladder involving the prostatic urethra
Abstract
Background: Intravesical bacillus Calmette-Guérin (BCG) is a treatment option for superficial (<or=T1) transitional cell carcinoma. Transitional cell carcinoma involving the prostatic urethra presents a treatment dilemma. Whereas prostatic urethral involvement might require radical cystectomy, select patients can be offered BCG and careful surveillance to preserve the bladder. We report long-term experience with BCG in this subset of patients with >5-year follow-up.
Patients and methods: Twenty-eight patients with high-risk superficial bladder cancer and prostatic urethral involvement were treated with once-weekly BCG for 6 weeks. Patients with prostatic stromal involvement were excluded. Maintenance was not used before 1995. Currently, we use maintenance BCG after induction. Patients were followed by cystoscopy/cytology and repeat biopsy to detect persistent and/or progressive disease.
Results: After 1 or 2 courses of once-weekly BCG for 6 weeks, 64.3% (18 of 28 of patients) exhibited a complete response in the bladder and prostate at their 6-month followup. Of those obtaining a complete response, 55.6% (10 of 18) experienced recurrence. Three recurrences were in the prostate: 1 isolated and 2 associated with multifocal bladder involvement. Twenty-eight percent (8 of 28 patients) underwent cystectomy because of failure of treatment to eradicate superficial disease or disease progression. Disease-specific survival was 89% (25 of 28 patients) at a median follow-up of 7.5 years.
Conclusion: Our long-term data support the durability of intravesical BCG in select patients with superficial bladder transitional cell carcinoma with prostatic urethral involvement. Follow-up biopsy of the prostatic urethra is mandatory and, if positive, cystectomy is indicated. One third of patients will require cystectomy for persistent or progressive disease; therefore, careful surveillance is critical.
Similar articles
-
Intravesical instillations with bacillus calmette-guérin for the treatment of carcinoma in situ involving prostatic ducts.Eur Urol. 2006 May;49(5):834-8; discussion 838. doi: 10.1016/j.eururo.2005.12.019. Epub 2006 Jan 6. Eur Urol. 2006. PMID: 16426729
-
Cystectomy in patients with high risk superficial bladder tumors who fail intravesical BCG therapy: pre-cystectomy prostate involvement as a prognostic factor.Eur Urol. 2005 Jul;48(1):53-9; discussion 59. doi: 10.1016/j.eururo.2005.03.021. Epub 2005 Apr 7. Eur Urol. 2005. PMID: 15967252
-
Bacillus Calmette-Guérin failure in patients with non-muscle-invasive urothelial carcinoma of the bladder may be due to the urologist's failure to detect urothelial carcinoma of the upper urinary tract and urethra.Eur Urol. 2014 Apr;65(4):825-31. doi: 10.1016/j.eururo.2013.09.049. Epub 2013 Oct 9. Eur Urol. 2014. PMID: 24144432
-
[Prostatic involvement by urothelial carcinoma in patients with bladder cancer and their implications in the clinical practice].Actas Urol Esp. 2012 Oct;36(9):545-53. doi: 10.1016/j.acuro.2012.02.005. Epub 2012 Apr 19. Actas Urol Esp. 2012. PMID: 22520044 Review. Spanish.
-
Urothelial carcinoma in the prostatic urethra and prostate: current controversies.Expert Rev Anticancer Ther. 2007 Mar;7(3):383-90. doi: 10.1586/14737140.7.3.383. Expert Rev Anticancer Ther. 2007. PMID: 17338657 Review.
Cited by
-
Long-term outcomes of intravesical therapy for non-muscle invasive bladder cancer.World J Urol. 2011 Feb;29(1):59-71. doi: 10.1007/s00345-010-0617-4. Epub 2010 Nov 28. World J Urol. 2011. PMID: 21113783 Review.
-
Diphtheria toxin-epidermal growth factor fusion protein DAB389EGF for the treatment of bladder cancer.Clin Cancer Res. 2013 Jan 1;19(1):148-57. doi: 10.1158/1078-0432.CCR-12-1258. Epub 2012 Nov 21. Clin Cancer Res. 2013. PMID: 23172881 Free PMC article.
-
Advanced primary urethral cancer: a case report.J Med Case Rep. 2019 Nov 29;13(1):365. doi: 10.1186/s13256-019-2253-y. J Med Case Rep. 2019. PMID: 31779706 Free PMC article.
-
ICUD-SIU International Consultation on Bladder Cancer 2017: management of non-muscle invasive bladder cancer.World J Urol. 2019 Jan;37(1):51-60. doi: 10.1007/s00345-018-2438-9. Epub 2018 Aug 14. World J Urol. 2019. PMID: 30109483 Review.
-
Organ-sparing procedures in GU cancer: part 3-organ-sparing procedures in urothelial cancer of upper tract, bladder and urethra.Int Urol Nephrol. 2019 Nov;51(11):1903-1911. doi: 10.1007/s11255-019-02232-z. Epub 2019 Jul 27. Int Urol Nephrol. 2019. PMID: 31352580 Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical